Nutritional status and quality of life of patients with advanced gastroenteropancreatic neuroendocrine neoplasms in Spain: the NUTRIGETNE (GETNE-S2109) study.

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Del Olmo-Garcia, Maribel
  • Hernandez-Rienda, Lorena
  • Garcia-Carbonero, Rocio
  • Hernando, Jorge
  • Custodio, Ana
  • Anton-Pascual, Beatriz
  • Gomez, Marta
  • Palma Milla, Samara
  • Suarez, Lorena
  • Bellver, Marta
  • Alonso, Vicente
  • Serrano, Raquel
  • Valdes, Nuria
  • Melian, Marcos
  • Febrero, Beatriz
  • Sampedro-Nunez, Miguel Antonio
  • Biarnes, Josefina
  • Diaz-Perez, Jose Angel
  • Molina-Cerrillo, Javier
  • Lopez, Carlos
  • Martinez Olmos, Miguel Angel
  • Capdevila, Jaume
  • NUTRIGETNE Group

Grupos

Abstract

Patients with advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) have impaired nutritional and physical performance due to the cancer pathophysiology and its treatment. The NUTRIGETNE study sought to characterize the nutritional status of patients with advanced GEP-NENs in Spain. This is a cross-sectional study that included patients with advanced GEP-NENs receiving active oncological treatment. Patients had a complete physical examination, anthropometry, bioelectrical impedance, dynamometry, laboratory analysis, and a comprehensive nutritional risk assessment. Malnutrition was defined according to Global Leadership Initiative on Malnutrition (GLIM) criteria. The study included 399 patients out of the 400 planned (Pearson's chi2; alpha 0.05). Median age was 62 years (22-83). Tumors most commonly originated in the small intestine (43.9%) and the pancreas (41.6%), 94.7% were metastatic, and 36.7%, 49.4%, and 12.5% were G1, G2, and G3, respectively. Malnutrition prevalence was 61.9% (25.8% moderate; 36.1% severe), mainly due to low muscle mass (50.9%), which was the most prevalent GLIM phenotypic criteria. Moreover, malnutrition showed a correlation with decreased hand grip strength (mean 23 vs 31.9kg; P <.001) and phase angle (median 5o vs 5.6o; P <.001). The prevalence of sarcopenia was 15%. Malnutrition was more frequent in patients with diabetes (74.4% vs 56.7%; P <.001), NECs (82.1% vs 60.3%; P =.062), and in those treated with chemotherapy (71.2% vs 59.7%; P =.058), whereas it did not correlate with tumor origin (P =.507), histological grade (P =.781), or functionality (P =.465). Malnutrition was correlated to body mass index (BMI) (P =.015), although it was also diagnosed in a high proportion of patients with no weight loss (63%, 54.1%, and 65.1% of patients with normal BMI, overweight, and obesity, respectively). Cachexia was present in 109 (27.3%) patients. Malnutrition is very prevalent and commonly underdiagnosed in patients with GEP-NENs. It is associated with sarcopenia and a worse QoL, requiring a multifactorial nutritional assessment. Certain factors such as the presence of diabetes may require closer monitoring due to a higher risk of malnutrition.

© The Author(s) 2025. Published by Oxford University Press.

Datos de la publicación

ISSN/ISSNe:
1083-7159, 1549-490X

ONCOLOGIST  OXFORD UNIV PRESS

Tipo:
Article
Páginas:
-
PubMed:
39998905
Enlace a otro recurso:
www.scopus.com
Factor de Impacto:
1,813 SCImago ℠
Cuartil:
Q1 SCImago ℠

Citas Recibidas en Web of Science: 9

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • nutritional status; malnutrition; sarcopenia; neuroendocrine neoplasms; gastroenteropancreatic

Cita

Compartir